COVID-19 and Dermal Fillers: Should We Really Be Concerned?
COVID y rellenos faciales ¿realmente debemos preocuparnos?
ACE2
ACE2 enzyme
COVID-19
Delayed immune reaction
Hyaluronic acid
Inflamación
Inflammation
Reacción inmunológica tardía
SARS-CoV-2
Ácido hialurónico
Journal
Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
24
02
2022
revised:
01
05
2022
accepted:
22
05
2022
pubmed:
7
6
2022
medline:
12
10
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
SARS-CoV-2 has caused millions of infections and deaths worldwide and case numbers continue to rise. Besides the effect of the virus on key organs - leading to respiratory illness, anosmia, diarrhea, and fever and other complications - delayed inflammatory reactions to hyaluronic acid dermal fillers, mainly in the face, have also been reported to occur after confirmed SARS-CoV-2 infections and in vaccinated individuals. While delayed inflammatory reactions tend to be self-limiting, they should be diagnosed and treated with corticosteroids, hyaluronidase, and/or antibiotics when necessary. The inflammation is generally not severe, yet these complications are classified as serious adverse events by the US Food and Drug Administration. They appear to be delayed type IV hypersensitivity reactions triggered by the immune system in the presence of SARS-CoV-2 or other viruses, such as those causing influenza, although the underlying mechanisms have not been fully elucidated. Because the longevity of dermal fillers is increasing, while the pandemic continues to evolve and new vaccines are under development, the long-term effects on hyaluronic acid fillers and other bioimplant materials should be studied. Physicians must also be encouraged to report these reactions, however mild, to ensure accurate records.
Identifiants
pubmed: 35659611
pii: S0001-7310(22)00468-9
doi: 10.1016/j.ad.2022.05.019
pmc: PMC9159960
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Dermal Fillers
0
Hyaluronic Acid
9004-61-9
Hyaluronoglucosaminidase
EC 3.2.1.35
Types de publication
Journal Article
Review
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
888-894Informations de copyright
Copyright © 2022 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
Références
Arch Dermatol Res. 2022 Jan;314(1):1-15
pubmed: 33559733
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
Dermatol Ther. 2021 Jan;34(1):e14644
pubmed: 33300274
Dermatol Surg. 2019 Aug;45(8):1085-1094
pubmed: 30789508
Clin Cosmet Investig Dermatol. 2020 May 07;13:345-349
pubmed: 32440187
Hum Pathol. 2020 Dec;106:106-116
pubmed: 33058948
Clin Cosmet Investig Dermatol. 2020 May 18;13:371-378
pubmed: 32547150
JAAD Case Rep. 2021 Apr;10:63-68
pubmed: 33681439
Arch Med Res. 2020 Oct;51(7):645-653
pubmed: 32611485
Breast. 2021 Oct;59:76-78
pubmed: 34174765
Brain Behav Immun. 2020 Jul;87:18-22
pubmed: 32240762
Clin Cosmet Investig Dermatol. 2021 Jul 16;14:921-934
pubmed: 34295171
Clin Cosmet Investig Dermatol. 2021 Jul 06;14:779-814
pubmed: 34276222
Crit Care. 2020 Jul 13;24(1):422
pubmed: 32660650
Eur J Intern Med. 2020 Jun;76:14-20
pubmed: 32336612
World J Clin Cases. 2021 Mar 6;9(7):1513-1523
pubmed: 33728295
J Drugs Dermatol. 2021 Apr 1;20(4):374-378
pubmed: 33852237
J Am Acad Dermatol. 2021 Jul;85(1):34
pubmed: 34112378
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e432-e433
pubmed: 33834559
J Cosmet Dermatol. 2021 May;20(5):1557-1562
pubmed: 33735503
J Cosmet Dermatol. 2021 Sep;20(9):2684-2690
pubmed: 34174156
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Dermatol Surg. 2002 Jun;28(6):491-4
pubmed: 12081677
Australas J Dermatol. 2020 Nov;61(4):362-366
pubmed: 32779184
Aesthet Surg J Open Forum. 2021 May 22;3(3):ojab021
pubmed: 34373851
Clin Exp Vaccine Res. 2021 May;10(2):151-153
pubmed: 34222128